Tesamorelin vs Sermorelin: Identities and Clinical Evidence
Published
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Tesamorelin vs sermorelin cannot be answered by ranking two interchangeable “growth-hormone peptides.” They are different molecules, and the clinical evidence examined here concerns different populations and goals. Tesamorelin has a currently labeled prescription product for excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin's former Geref products are listed by FDA as discontinued.
Direct answer: Tesamorelin's HIV-lipodystrophy trials and sermorelin's older pediatric growth study do not establish which is better for general weight loss, muscle gain or anti-aging. Neither a shared signaling pathway nor a historical approval transfers those findings to unrelated uses or research vials.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. It compares identities, study evidence and regulatory documents without recommending treatment.

What is the molecular difference?
Both compounds belong to the growth-hormone-releasing hormone family, but their structures differ. Tesamorelin is based on the 44-amino-acid human growth-hormone-releasing factor sequence with an N-terminal modification. Sermorelin corresponds to the 1–29 fragment. Shared ancestry does not establish matching exposure, effects or clinical uses. Current EGRIFTA WR prescribing information, original sermorelin study
Comparison | Tesamorelin | Sermorelin |
|---|---|---|
Molecular framework | Modified 44-amino-acid GHRF analog | GHRH 1–29 fragment |
Key population in the cited efficacy study | Adults with HIV and excess abdominal fat | Prepubertal children with growth-hormone deficiency |
Main measured outcome | Visceral abdominal fat assessed by CT | Linear growth velocity |
US product context checked November 11, 2026 | Current EGRIFTA WR label | Geref records list discontinued products |
Unsupported extrapolation | General weight-loss or anti-aging benefit | Adult body-composition or anti-aging benefit |
For readers comparing other members of this pathway, the CJC-1295 identity guide explains why a modification can change the compound being discussed.
What did the tesamorelin trial show?
Falutz and colleagues' 2007 randomized trial enrolled 412 adults with HIV and abdominal fat accumulation; most participants were men. Over 26 weeks, the study compared tesamorelin with placebo and measured visceral adipose tissue using CT. The results supported a reduction in that specific fat compartment under the trial conditions. Original trial abstract
Visceral fat is not the same endpoint as total body weight. A result for CT-measured abdominal fat in this defined population cannot simply be restated as a general weight-loss percentage or applied to adults without HIV. The trial also reported more withdrawals for adverse events with tesamorelin, even though overall adverse-event rates did not differ significantly.
A subsequent extension examined continued treatment and treatment withdrawal. Visceral fat reaccumulated after participants stopped tesamorelin. This informs durability; it does not show that a short treatment period permanently changes body composition. The extension followed the earlier study rather than providing a wholly independent new starting population. Falutz and colleagues, 2008
These findings support a specific research and prescribing context. Our tesamorelin evidence guide examines that context in greater depth.
What did the sermorelin study show?
The 1996 Geref International Study Group report enrolled 110 previously untreated, prepubertal children with growth-hormone deficiency; 86 were eligible for the efficacy analysis. It was a multicenter, open-label study lasting up to one year. Investigators measured growth velocity, bone age and safety-related outcomes. Growth velocity increased compared with the children's pretreatment baseline. Thorner and colleagues, 1996
That result concerns childhood linear growth in a defined deficiency population. It does not measure adult fat loss, muscle strength, sleep quality or lifespan. The absence of a concurrent control group also limits causal interpretation, and a one-year growth-velocity result is not the same as demonstrated final adult height.
Study comparison | Tesamorelin trial | Sermorelin study |
|---|---|---|
Design | Randomized, placebo-controlled | Open-label; comparison with baseline |
Initial study period | 26 weeks | Up to one year |
Outcome relevant to the question | Visceral fat in adults with HIV | Height velocity in GH-deficient children |
Direct comparison with the other peptide? | No | No |
Placing these results side by side helps identify the evidence gap. It cannot calculate a meaningful “winner”: the participants, comparators and endpoints differ. A direct adult comparison would need a defined population, a shared clinical outcome and adequate safety follow-up.
What is the current US product status?
Tesamorelin: a specific current indication
The EGRIFTA WR DailyMed record, updated July 29, 2026, indicates the product for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It explicitly excludes weight-loss management and says long-term cardiovascular safety has not been established. WR and SV formulations are not substitutable. Current official label
The label also addresses malignancy, elevated IGF-I, fluid retention, glucose intolerance or diabetes, and hypersensitivity. Those limitations belong alongside the efficacy discussion. Approval for a named prescription product does not authenticate another manufacturer's research material or establish its clinical suitability.
Sermorelin: discontinued does not mean withdrawn for harm
The current Drugs@FDA records list Geref products under both NDA 020443 and NDA 019863 as discontinued. These records cover different former product presentations; neither should be presented as a currently marketed Geref product.
FDA's 2013 determination says those products were not withdrawn for reasons of safety or effectiveness. The notice describes earlier withdrawal of their approvals at the company's request. That distinction prevents an inaccurate claim that discontinuation proves a safety failure. It also does not approve a current compounded preparation or research vial, or establish efficacy for adult anti-aging uses. FDA's Federal Register determination
The growth-hormone research hub and study-reading guide offer related comparisons focused on study design and evidence boundaries.
Review method and source access
Reviewed November 11, 2026. This appraisal used current official product records, the full EGRIFTA WR label, FDA's historical determination and original trial abstracts. Full journal texts were not available for all cited studies. The examples are not an exhaustive review of every GHRH study and do not establish that no other population has been studied. No independent clinical review is claimed.
Catalog materials are for lawful laboratory research only, not human or veterinary use. Published studies do not verify a supplied lot.
